2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149848
    MMP-9-IN-6 2241964-36-1 99.80%
    MMP-9-IN-6 (Compound 3g) is a MMP-9 inhibitor with IC50 value of 50 μM, which has good anti-ulcer effect.
    MMP-9-IN-6
  • HY-150019
    PI3K-IN-36 1401436-93-8 98.76%
    PI3K-IN-36 (compound A68) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL).
    PI3K-IN-36
  • HY-150051
    IL-2-IN-1 245747-10-8 99.95%
    IL-2-IN-1 is a potent IL-2 inhibitor with an IC50 value of 1978 nM. IL-2-IN-1 shows antiproliferative activities.
    IL-2-IN-1
  • HY-150746
    ODN 24991 1682661-49-9 99.64%
    ODN 24991, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a TLR3, TLR7 and TLR9 (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 24991 disrupts TLR3-, TLR7- and TLR9-mediated immune cell immune responses. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3'.
    ODN 24991
  • HY-151873
    SZM679 3027645-52-6 99.59%
    SZM679 is a potent, orally active and selective RIPK1 inhibitor with Kd values of 8.6 nM and >5000 nM for RIPK1 and RIPK3, respectively. SZM679 reverses the tumor necrosis factor-induced systemic inflammatory response. SZM679 decreases the Tau hyperphosphorylation, neuroinflammation, and the RIPK1 phosphorylation level in the hippocampus and cortex. SZM679 can be used in research of Alzheimer's disease (AD).
    SZM679
  • HY-152080
    Blovacitinib 2411222-97-2 99.71%
    Blovacitinib (TUL01101) is a potent, selective and orally active JAK1 inhibitor, with an IC50s of 3, 37, 1517 and 36 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Blovacitinib can be used for the research of rheumatoid arthritis.
    Blovacitinib
  • HY-15315S
    Baricitinib-d5 1564241-79-7 98.98%
    Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.
    Baricitinib-d5
  • HY-153377
    Lipid 14 2430034-05-0
    Lipid 14 is an ionizable amino lipid. Lipid 14 delivers mRNA into target cells, significantly enhancing the in vivo expression efficiency and immunogenicity of mRNA. Lipid 14 can be used to synthesize lipid nanoparticles (LNPs). Lipid 14 can be used for studies of SARS-CoV-2 and Yersinia pestis.
    Lipid 14
  • HY-153460
    TLR7/8/9 antagonist 2 2920729-91-3 98.96%
    TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis.
    TLR7/8/9 antagonist 2
  • HY-153525
    FXR agonist 5 2414008-05-0 99.83%
    FXR agonist 5 (compound 1) is a FXR agonist. FXR agonist 5 can be used for research in diseases or disorders caused by metabolic inflammation.
    FXR agonist 5
  • HY-153711
    TRPA1-IN-2 2415206-22-1 99.82%
    TRPA1-IN-2 (compound 1) is a potent and orally active TRPA1 inhibitor with an IC50 value of 0.04 µM. TRPA1-IN-2 shows anti-inflammation activity.
    TRPA1-IN-2
  • HY-153764
    IDO-IN-18 314027-92-4
    IDO-IN-18 (Compound 00815) is an IDO inhibitor. IDO-IN-18 can be used for research of immunosuppression associated infectious or cancer diseases.
    IDO-IN-18
  • HY-15448A
    (Rac)-Tezacaftor 1226709-85-8
    (Rac)-Tezacaftor ((Rac)-VX-661) is a racemate of Tezacaftor (HY-15448). Tezacaftor is a F508del CFTR corrector. (Rac)-Tezacaftor can be used for the research of cystic fibrosis.
    (Rac)-Tezacaftor
  • HY-15473A
    MLN120B dihydrochloride 1782573-78-7 99.73%
    MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis.
    MLN120B dihydrochloride
  • HY-155191
    Galectin-3/galectin-8-IN-1 3053895-85-2 99.53%
    Galectin-3/galectin-8-IN-1 (Compound 53) is a dual Galectin-3 and galectin-8 C-terminal domain inhibitor, with Kd values of 4.12 μM and 6.04 μM respectively. Galectin-3/galectin-8-IN-1 inhibits the MRC-5 lung fibroblast cells migration. Galectin-3/galectin-8-IN-1 can be used for research of cancer and tissue fibrosis.
    Galectin-3/galectin-8-IN-1
  • HY-155487
    JTE-151 1404380-58-0 99.34%
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research.
    JTE-151
  • HY-155516
    KV1.3-IN-1 3052324-00-9 98.34%
    KV1.3-IN-1 (Compound trans-18) is a KV1.3 channel inhibitor (IC50: 230 nM and 26.12 nM in Ltk cells and PHA-activated T-lymphocytes respectively). KV1.3-IN-1 impairs intracellular Ca2+ signaling. KV1.3-IN-1 inhibits T-cell activation, proliferation, and colony formation.
    KV1.3-IN-1
  • HY-155539
    Cisd2 agonist 2 2916371-59-8 99.17%
    Cisd2 agonist 2 (compound 6) is a Cisd2 activator (EC50=191 nM), and Cisd2 levels are associated with non-alcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant in vivo toxicity in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout). Cisd2 (CDGSH iron sulfur domain 2) is a zinc finger protein that is mainly localized in the endoplasmic reticulum or mitochondrial membrane. Cisd2 participates in mitochondrial function by forming homodimers containing two redox-active 2Fe-2S clusters.
    Cisd2 agonist 2
  • HY-156769
    Cbl-b-IN-13 2368841-85-2 98.46%
    Cbl-b-IN-13 (Example 520) is a Cbl-b inhibitor with an IC50 of <100 nM. Cbl-b-IN-13 has the ability to activate T-cells.
    Cbl-b-IN-13
  • HY-157281
    Photolumazine III 23140-55-8 99.96%
    Photolumazine III (PLIII) is a microbial metabolite and derivative of Riboflavin (HY-B0456). Photolumazine III binds MR1 with high specificity. Photolumazine III supports efficient TCR binding. Photolumazine III acts as an antigen to activate cells. Responses to Photolumazine III trigger immune reactions.
    Photolumazine III
Cat. No. Product Name / Synonyms Application Reactivity